Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCH: Vistusertib +/- Rituximab in Relapsed/Refractory DLBCL
NCT02752204Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Oct 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vistusertib in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Birmingham. Started Oct 2015; status: completed.
02
Drugs
vistusertib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02752204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752204.